Brodalumab in psoriasis: evidence to date and clinical potential

Amy C Foulkes BMedSci (Hons), BMBS, MRCP (Derm), PhD, Richard B Warren BSc (Hons), MBChB (Hons), MRCP, PhD

Article Type

Review

Published

This article reviews brodalumab’s place in the expanding armamentarium of cytokine-directed therapies for patients with severe psoriasis.

Read more

Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?

Francesco Menzella MD, Mirella Biava Msc, Diego Bagnasco MD, PhD, Carla Galeone Msc, Anna Simonazzi MD, Patrizia Ruggiero Msc, Nicola Facciolongo MD

Article Type

Review

Published

This article is an indirect comparison among literature data, especially between OCS reduction studies (ZONDA-SIRIUS) and pivotal studies (SIROCCO-MENSA), evaluating whether the clinical efficacy and the steroid-sparing effect of benralizumab may represent an advantage over other compounds. This data could help the clinician in the decision process of treatment choice, within the different available therapeutic options for eosinophilic refractory severe asthma.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.